Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program

Diabetes

Volumn 57, Issue 4, 2008, Pages 980-986

  Mather, Kieren J ^a,c   Funahashi, Tohru ^b   Matsuzawa, Yuji ^b   Edelstein, Sharon ^c   Bray, George A ^d   Kahn, Steven E ^e   Crandall, Jill ^f   Marcovina, Santica ^g   Goldstein, Barry ^h   Goldberg, Ronald ⁱ  

^a INDIANA UNIVERSITY   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; METFORMIN; PLACEBO; ADIPONECTIN, HUMAN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ETHNICITY; FEMALE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RISK; SEX DIFFERENCE; WEIGHT REDUCTION; BLOOD; ETHNIC GROUP; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; LIFESTYLE; MIDDLE AGED; REFERENCE VALUE; RISK FACTOR;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS; DISEASE PROGRESSION; ETHNIC GROUPS; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS;

EID: 42449162285     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1419     Document Type: Article

References (36)

1. Snehalatha C, Mukesh B, Simon M, et al.: Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226-3229, 2003
2. Halperin F, Beckman JA, Patti ME, et al.: The role of total and high-molecular-weight complex of adiponectin in vascular function in offspring whose parents both had type 2 diabetes. Diabetologia 48:2147-2154, 2005
3. Kadowaki T, Yamauchi T, Kubota N, et al.: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
4. Goldstein BJ, Scalia R: Adipokines and vascular disease in diabetes. Curr Diab Rep 7:25-33, 2007
5. Lindsay RS, Funahashi T, Hanson RL, et al.: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
6. Duncan BB, Schmidt MI, Pankow JS, et al.: Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 53:2473-2478, 2004
7. Spranger J, Kroke A, Mohlig M, et al.: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817, 2003
8. Knobler H, Benderly M, Boyko V, et al.: Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur J Endocrinol 154:87-92, 2006
9. Choi KM, Lee J, Lee KW, et al.: Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 61:75-80, 2004
10. Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
11. Yamamoto Y, Hirose H, Saito I, et al.: Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87-90, 2004
12. Daimon M, Oizumi T, Saitoh T, et al.: Decreased serum levels of adiponec-tin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata Study. Diabetes Care 26:2015-2020, 2003
13. Fumeron F, Aubert R, Siddiq A, et al.: Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the Epidemiologic Data on the Insulin Resistance Syndrome Prospective Study. Diabetes 53:1150-1157,2004
14. Nakashima R, Kamei N, Yamane K, et al.: Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 91:3873-3877, 2006
15. Snijder MB, Heine RJ, Seidell JC, et al.: Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn Study. Diabetes Care 29:2498-503, 2006
16. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
17. Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
18. Kubota N, Terauchi Y, Yamauchi T, et al.: Disruption ofadiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-6, 2002
19. Pajvani UB, Hawkins M, Combs TP, et al.: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-medi-ated improvement in insulin sensitivity. J Biol Chem 279:12152-62, 2004
20. Nawrocki AR, Rajala MW, Tomas E, et al.: Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to per-oxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654-2660, 2006
21. The Diabetes Prevention Program: Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634, 1999
22. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23:1619-1629, 2000
23. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
24. Knowler WC, Hamman RF, Edelstein SL, et al.: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005
25. Orchard TJ, Temprosa M, Goldberg R, et al.: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142:611-619, 2005
26. Crandall J, Schade D, Ma Y, et al.: The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 61:1075-1081, 2006
27. Walker EA, Molitch M, Kramer MK, et al.: Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29:1997-2002, 2006
28. Kitabchi AE, Temprosa M, Knowler WC, et al.: Role ofinsulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54:24042414, 2005
29. Nishimura A, Sawai T: Determination ofadiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta 371:163-168, 2006
30. Cox DR: Regression models and life-tables. JRSS (B) 74:187-220, 1972
31. Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29:2102-2107, 2006
32. Cnop M, Havel PJ, Utzschneider KM, et al.: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459-469, 2003
33. Lachin JM, Christophi CA, Edelstein SL, et al.: Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 56:1153-1159, 2007
34. Zhou G, Myers R, Li Y, et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
35. Shaw RJ, Lamia KA, Vasquez D, et al.: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646, 2005
36. Yamauchi T, Kamon J, Ito Y, et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003